Introduction
The idiopathic, genetic, and generalized condition known as juvenile myoclonic epilepsy (JME), often referred to as Janz syndrome and impulsive petit mal, is a kind of epilepsy. Herpin first identified it in 1867; later, Janz and Christian defined it as an "impulsive petit mal" in 1957; and Lund identified it as JME in 1975. Absence, myoclonic, and generalized tonic-clonic seizures are its defining features.
What Is the Etiology Behind Juvenile Myoclonic Epilepsy?
JME is categorized as idiopathic and hereditary (around 50% of cases have a positive family history). Juvenile myoclonic epilepsy (JME) still has an elusive specific cause. Genetic factors play a significant role in genetic generalized epilepsy (GGE), which is the name used to describe the complete class of idiopathic (genetic) generalized epilepsies (IGEs). JME is the IGE with the most accurately discovered particular mutations in a variety of genes. Its route of inheritance is complicated, and numerous genes most likely contribute to a comparable electroclinical condition.
Ion channel gene mutations, such as those in the chloride channel (CLCN2), GABA receptor subunit (GABRA1), and beta-4 calcium channel subunit (CACNB4), have been linked to JME. These channelopathies are all uncommon causes of JME, and each has only been documented in a single family.
The most frequent gene mutation discovered thus far in research on families with JME is in 3FHC1, a gene involved in cortical genesis throughout brain development. Dysfunction in afflicted patients with JME and an EFHC1 gene mutation may be caused by calcium dysregulation rather than anomalies during cortical development. Researchers are also looking into gene malfunction at other loci (EJM2, EJM3).
What Is the Epidemiology of Juvenile Myoclonic Epilepsy?
One of the most prevalent childhood or juvenile epilepsy syndromes, JME accounts for five percent to ten percent of all epilepsy cases. JME affects both sexes equally, despite some research claiming that females are likelier to get it. JME typically shows symptoms between the ages of 12 and 18.
What Is the Pathophysiology of Juvenile Myoclonic Epilepsy?
JME contains both idiopathic and genetic components to its pathogenesis. Although a complex process is suspected, the genetics of inheritance remains poorly understood. Some genes with recognized connections to JME are CACNB4, EFHC1, and GABRA1. There have been reports of structural anomalies as a potential cause of JME, although magnetic resonance imaging (MRI) of the brain is unremarkable in cases with classic JME.
Historical Background:
In most JME patients, seizures begin between 12 and 18, with a mean onset of roughly 15 years. However, with an age range of 5 to 34 years, the beginning can occur sooner or later. As noted in the introduction, absence, myoclonic, and generalized tonic-clonic (GTC) seizures are present in JME. All JME patients experience myoclonic seizures, followed by GTC seizures in 85 % to 90 % of cases and absence seizures in roughly 20 % to 40 % of cases.
The hallmark of this disorder, myoclonic seizures, is required to diagnose JME. Rarely will they appear to be the only seizure kind. Brief, typically bilateral, jerky movements of the arms and occasionally the legs are described, as well as the retention of consciousness. Myoclonic seizures could be misdiagnosed as twitches, anxiety or nervousness. Myoclonic jerks in clusters become more frequent and intense and frequently develop into GTC seizures. Myoclonic seizures typically start a few months following GTC seizures.
What Is the Evaluation for Juvenile Myoclonic Epilepsy?
The majority of the information needed to diagnose JME comes from history. In general, physical examinations are unremarkable. For the purpose of diagnosing JME, an electroencephalogram (EEG) is supportive evidence. Nearly all JME patients have aberrant interictal EEGs. A nocturnal and sleep-deprived EEG is abnormal in almost every patient if the routine EEG is normal. The anomalies are primarily noticeable when someone is waking up from sleep.
The usual EEG in JME exhibits frontocentral predominance and diffuse, symmetric, bilateral four to six hertz (Hz) polyspike and wave discharges. About half of the patient population will have localized or asymmetric problems, and the backdrop has a normal alpha rhythm.
Polyspike discharges accompanying myoclonic jerks at 10 to 16 Hz are visible on ictal or continuous EEG recordings. The spikes and myoclonic jerks are correlated.
Like other epilepsies, GTC and absence seizures associated with JME include low voltage rapid activity with spike and wave discharges and generalized 3 Hz spike and wave discharges, respectively, on the EEG. Given that JME is known to be photosensitive, photic stimulation increases the yield of the EEG in this condition.
What Are the Treatment Options for Juvenile Myoclonic Epilepsy?
Anti-epileptic medicines (AEDs) can easily control JME; monotherapy is adequate for most patients. The best medication for treating JME is Valproic acid, the drug of preference. It is a broad-spectrum drug that manages all JME seizure types. Given its well-known teratogenic potential, its use in women of reproductive age requires extreme caution. Levetiracetam, Lamotrigine, Topiramate, and Zonisamide are further therapeutic choices. Lamotrigine can exacerbate myoclonic seizures, yet it is frequently used to treat JME because it manages other seizure types. Ethosuximide can be used as a treatment option if only absence seizures are detected. Myoclonic jerks can be prevented by using Clonazepam. Among the contraindicated medications include Phenytoin (a sodium channel blocker), Oxcarbazepine, and Carbamazepine is given which can make absence and myoclonic seizures worse. However, they may be effective in the management of JME GTC seizures. Vigabatrin, Tiagabine, Gabapentin, Pregabalin, and Primidone are further drugs to stay away from. Only a few people with JME experience persistent disease, and in these patients, combination therapy with or without vagal nerve stimulation (VNS) may be an option.
What Is the Prognosis of Juvenile Myoclonic Epilepsy?
In most JME patients, seizures are typically well controlled with medication, and they typically improve during the fourth decade of life. However, JME requires lifetime treatment (even after a lengthy period without seizures), as the likelihood of return is significant if medication is stopped.
Conclusion
While a neurologist oversees most JME management, the primary care or nurse practitioner typically does follow-up. The inter-professional team's patient education efforts are essential for seizure prevention. Chemists should inform patients and their families of the significance of compliance and side effects. Neuroscience nurses monitor patients, educate others, and update the team on any changes to their conditions. Avoiding precipitating variables and triggers needs to be a top priority. Avoiding alcohol use, exhaustion, stress, lack of sleep, any flashing light, non-compliance with medicine, hunger, temperature extremes, and drug use are a few of these.
Additionally, patients should be instructed about the dangers of driving, operating heavy equipment, swimming, avoiding heights, and being alone near a fire. Because there is a substantial risk of return if medication is stopped, the treatment is typically lifelong (even after a lengthy period of seizure-free time). The dangers vs. benefits of taking drugs while pregnant should be thoroughly discussed with the patient, as with any epilepsy syndrome.
